Business Wire

Flowsion A/S Wins Horizon 2020 SME Instrument Grant for Automatic Glucose Control in Intensive Care Medicine

Del

Flowsion, the Denmark-based developer of continuous blood glucose systems for intensive care medicine, has won a prestigious European Commission Horizon 2020 SME Instrument award.

The grant was awarded to assist in the development of an innovative automatic blood glucose control system, Glucostat, developed by Flowsion. Glucostat is expected to reduce mortality, morbidity, length of stay and treatment costs dramatically for intensive care patients compared to existing technologies.

“It’s a welcome validation of our innovative, patented technology and a confirmation that we are addressing a really significant problem with a globally-relevant market opportunity,” said Hans Jorgen Pedersen, CEO of Flowsion. “Flowsion has already performed clinical studies with the system so we now that Glucostat will fulfil the demands of the intensive care units.”

With 5-8 % success rate the European Innovation Council SME Instrument awards are exceptionally competitive, and only 3018 companies across Europe were awarded a grant until now.

“This kind of technology is really crucial for intensive care medicine, where patients’ lifes are threatened every day. Glucose control has proven to be very difficult to perform for the intensive care units in hospitals world wide, and now getting a system that automatically helps performing blood glucose control will increase survival rate and lower treatment costs at the same time” said Hans Jorgen Pedersen. “We’ve carefully studied several technologies and designed a solution that is really elegant and simple to use, but that also delivers an enormous value for patients, doctors, nurses and hospitals.”

The SME Instrument programme is designed to assist internationally-oriented SMEs in implementing high-risk and high-potential innovation ideas. It aims at supporting projects with a European dimension that lead to major changes in how business is done.

About Flowsion
Flowsion is a European medical device company focusing exclusively on the needs of intensive care unit patients. Flowsion will launch new projects later on with other continuous measurement and control technologies for the ICU patients. More information can be found at: http://flowsion.dk

Contact information

Flowsion
Hans J. Pedersen
+45 4017 3150
Email: info@flowsion.dk
Website: www.flowsion.dk

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Andersen Global Welcomes Tufiño & Villegas in Bolivia25.9.2018 13:30Pressemelding

Andersen Global continues its growth in Latin America with news that one of the premier tax law firms in Bolivia, Estudio Jurídico Tufiño Villegas & Asoc., has become a collaborating firm of Andersen Global. Tufiño & Villegas specializes in providing legal services to both local and foreign corporations that do business in Bolivia. With offices in La Paz, Santa Cruz and Cochabamba, the signing of a Collaboration Agreement with Tufiño & Villegas kickstarts Andersen Global’s presence in the South American country. The international organization has almost doubled its headcount in Latin America in the past eight months. Through its member firms and collaborating firms, Andersen Global already has a strong presence in the region in several major economic hubs – Mexico, Guatemala, Panama, Chile, Uruguay, Ecuador, Brazil, and most recently Paraguay. Led by Founders and Managing Partners Alvaro Villegas Aldazosa and Jose Luis Tufiño, the firm, Tufiño & Villegas, was created in 1995 as a tax b

Arensis and Schneider Electric Launch Smart Microgrid Partnership and Development of ENTRADE IO Blockchain Technology25.9.2018 13:00Pressemelding

Arensis, a leading international provider of decentralized energy systems, and Schneider Electric, a leader in microgrid development with integrated efficiency solutions combining energy, automation and software, today announced the joint development of its smart microgrid pilot program. As part of the pilot, Arensis and Schneider Electric will develop a blockchain Application Programming Interface (API) platform for ENTRADE IO, a newly-formed company founded by the CEO of Arensis for off grid project financing and the sale of renewable energy in remote areas around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005362/en/ Schneider Electric augmented reality (AR) applications developed for Arensis and ENTRADE IO Smart Microgrid solutions. (Graphic: Business Wire) Joint development of the smart microgrid systems, combining waste-to-energy, solar and storage, will launch in North America with plans for growth

Clarke Valve Closes $5.5 Million Venture Funding Round Led by OGCI Climate Investments25.9.2018 13:00Pressemelding

Clarke Valve today completed the sale of $5.5 million of Series B Preferred Stock to a group of investors led by OGCI Climate Investments. Along with funding from Saudi Aramco Energy Ventures and Chevron Technology Ventures, Clarke has now raised $15.5 million of Series B funding. Clarke’s patented Shutter Valves are typically 1/5th the weight, 1/5th the size and 1/5th the cost of equivalent legacy valves, providing substantial benefits to users of industrial control valves in many industries. In addition, Clarke valves are currently the only control valves in the world to achieve the stringent American Petroleum Institute (API) 641 certification for low fugitive emission performance. Fugitive emissions from legacy valve designs is the cause of significant methane emitted to the atmosphere from industrial facilities. Pratima Rangarajan, CEO of OGCI Climate Investments, said “We are pleased to support the Clarke team in its journey to reach a global market. We believe that the Clarke Va

Analogix Introduces Industry’s Lowest Power eDP TCON with In-Cell Touch for Latest Generation Notebooks25.9.2018 13:00Pressemelding

Analogix Semiconductor, Inc. today announced its ANX2403, the industry’s lowest power Full HD embedded DisplayPort™ 1.4 (eDP) timing controller (TCON) with panel self-refresh (PSR), VESA DisplayHDR™ 400 support, and in-cell finger and active stylus touch for notebook PCs with graphics display resolution up to 1920x1280. Leveraging Analogix’s technology leadership in low-power processes, the ANX2403 reduces the Full HD 60Hz power consumption to 60mW using 28nm process technology, a 35% reduction over the 40nm technology and more than 50% reduction over the 55nm technology, becoming the lowest power TCON in the industry. Moreover, the ANX2403 supports Intel low refresh rate (LRR) and PSR2 for even further power reductions. “The ANX2403 brings together our capabilities in low-power processes, in-cell touch, and high-dynamic-range (HDR) technology, offering the lowest power consumption to date, better image performance, and thinner panels with reduced bezels at a lower cost to display pane

Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC25.9.2018 12:32Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced results from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial, demonstrating that ALUNBRIG reduced the risk of disease progression or death, known as progression-free survival (PFS), as assessed by a blinded independent review committee (BIRC), by more than fifty percent compared to crizotinib in adults with anaplastic lymphoma kinase-positive (ALK+) locally advanced or metastatic non-small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor. Findings from the first interim analysis of the ALTA-1L trial will be presented during the Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC) in Toronto on Tuesday, September 25, 2018. The data were also simultaneously published online in The New England Journal of Medicine. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSC

Softomotive and Enate Partner to Help Clients Orchestrate Workflows across Their RPA Ecosystem25.9.2018 12:15Pressemelding

Softomotive, a leading Robotic Process Automation (RPA) vendor, has announced a strategic partnership with Enate, the pioneering Robotic Service Orchestration (RSO) provider. Together, Softomotive and Enate will allow business enterprises of all sizes to go further and faster with their automation programmes, achieving greater efficiency through orchestration of workflows between human employees and software robots. This partnership will offer Softomotive and Enate’s mutual customers the flexibility to orchestrate workflow between humans and bots whether the enterprise is using just Softomotive bots or more than one RPA provider. “As the RPA market matures, we are finding more and more clients are relying on more than one RPA provider, ” said Marios Stavropoulos, Softomotive’s CEO. “This adds an extra layer of complexity and Softomotive is all about simplifying things for our clients. This new partnership with Enate will do just that by allowing them to continue to orchestrate combined